key: cord-0692427-p9ds5w2c
authors: Tavabie, Oliver D; Abeysekera, Kushala W M; Tranah, Thomas H; Nayagam, Jeremy S; Aluvihare, Varuna R
title: COVID-19 and liver transplantation: the jury is still out
date: 2020-10-30
journal: Lancet Gastroenterol Hepatol
DOI: 10.1016/s2468-1253(20)30313-7
sha: eb8f0cef202506f0569482191e547ffadf2d53b0
doc_id: 692427
cord_uid: p9ds5w2c

nan

Predominant aetiology of liver disease, access to LTx assessment (private healthcare or state sponsored), LTx assessment process Procedural

Graft selection (DBD v DCD v LDLT, HCV and HBcAb positive grafts) and/or allocation, surgical approach and techniques

Immunosuppression regimens including target trough titres and preparations, co-morbidity management and screening (e.g. hypertension, diabetes and renal failure) Table 1 . Potential variables which may differ between LTx centres nationally and internationally 1, 2 . Abbreviations:-donation after brain death (DBD), donation after cardiac death (DCD), living donor liver transplantat (LDLT), hepatitis C (HCV), Hepatitis B core antibody (HBcAb)

International comparison of liver transplant programmes: differences in indications, donor and recipient selection and outcome between Italy and the UK

Liver transplantation around the world